Since no recommendations are available regarding the management of patients with a history of IBD before starting an anti-IL-17 drug, it is of great importance to complete comprehensive patient history assessments, including the patient’s personal and family history of inflammatory bowel disease and other IMIDs before initiating treatment to help guide selection of the most appropriate management options. This evidence concerns the gene IL17A and inflammatory bowel disease.